Understanding how nuclear defects contribute to ALS and frontotemporal dementia
Defining the Mechanisms and Consequences of Nuclear Defects in ALS/FTD
This study is looking at how certain problems in brain cells contribute to diseases like ALS and frontotemporal dementia, and it aims to find new ways to help protect these cells and improve treatments for people affected by these conditions.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rhode Island NIH-funded |
| Lab location | 1 site (Kingston, United States) |
| Project ID | NIH-11045052 on NIH RePORTER |
What this research studies
This research investigates the molecular defects that lead to neuronal death in conditions like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). It focuses on the role of the nuclear pore complex and nucleocytoplasmic transport in these diseases, aiming to uncover how these defects affect neuronal resilience. By using advanced techniques, including pharmacological and genetic approaches, the study will explore the interactions between actin and the nuclear pore complex in neurons with specific genetic mutations. The ultimate goal is to identify new pathways that could be targeted for therapeutic interventions.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with amyotrophic lateral sclerosis or frontotemporal dementia.
Not a fit: Patients with other neurodegenerative diseases not related to ALS or FTD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve neuronal health and resilience in patients with ALS and FTD.
How similar studies have performed: While the specific mechanisms being investigated are novel, previous research has shown that targeting cellular pathways can lead to improvements in neurodegenerative conditions.
Where this research is happening
Kingston, United States
- University of Rhode Island — Kingston, United States (Active)
Researchers
- Principal investigator: Fallini, Claudia — University of Rhode Island
- Study coordinator: Fallini, Claudia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.